228 related articles for article (PubMed ID: 25989942)
1. Synergistic anti-tumor efficacy of doxorubicin and flavopiridol in an in vivo hepatocellular carcinoma model.
Kwak MS; Yu SJ; Yoon JH; Lee SH; Lee SM; Lee JH; Kim YJ; Lee HS; Kim CY
J Cancer Res Clin Oncol; 2015 Nov; 141(11):2037-45. PubMed ID: 25989942
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia and retinoic acid-inducible NDRG1 expression is responsible for doxorubicin and retinoic acid resistance in hepatocellular carcinoma cells.
Jung EU; Yoon JH; Lee YJ; Lee JH; Kim BH; Yu SJ; Myung SJ; Kim YJ; Lee HS
Cancer Lett; 2010 Dec; 298(1):9-15. PubMed ID: 20573444
[TBL] [Abstract][Full Text] [Related]
3. Synergistic anti-tumor efficacy of lovastatin and protein kinase C-beta inhibitor in hepatocellular carcinoma.
Kim W; Yoon JH; Kim JR; Jang IJ; Bang YJ; Kim YJ; Lee HS
Cancer Chemother Pharmacol; 2009 Aug; 64(3):497-507. PubMed ID: 19096848
[TBL] [Abstract][Full Text] [Related]
4. Antisense hypoxia-inducible factor 1alpha gene therapy enhances the therapeutic efficacy of doxorubicin to combat hepatocellular carcinoma.
Liu F; Wang P; Jiang X; Tan G; Qiao H; Jiang H; Krissansen GW; Sun X
Cancer Sci; 2008 Oct; 99(10):2055-61. PubMed ID: 19016766
[TBL] [Abstract][Full Text] [Related]
5. Synergistic antitumoral activity and induction of apoptosis by novel pan Bcl-2 proteins inhibitor apogossypolone with adriamycin in human hepatocellular carcinoma.
Mi JX; Wang GF; Wang HB; Sun XQ; Ni XY; Zhang XW; Tang JM; Yang DJ
Acta Pharmacol Sin; 2008 Dec; 29(12):1467-77. PubMed ID: 19026166
[TBL] [Abstract][Full Text] [Related]
6. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
[TBL] [Abstract][Full Text] [Related]
7. Ribavirin augments doxorubicin's efficacy in human hepatocellular carcinoma through inhibiting doxorubicin-induced eIF4E activation.
Tan J; Ye J; Song M; Zhou M; Hu Y
J Biochem Mol Toxicol; 2018 Jan; 32(1):. PubMed ID: 29112301
[TBL] [Abstract][Full Text] [Related]
8. Retinoblastoma tumor suppressor gene expression determines the response to sequential flavopiridol and doxorubicin treatment in small-cell lung carcinoma.
Budak-Alpdogan T; Chen B; Warrier A; Medina DJ; Moore D; Bertino JR
Clin Cancer Res; 2009 Feb; 15(4):1232-40. PubMed ID: 19174488
[TBL] [Abstract][Full Text] [Related]
9. The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
Jiang H; Dong Q; Luo X; Shi B; Wang H; Gao H; Kong J; Zhang J; Li Z
Cancer Lett; 2014 Jan; 342(1):113-20. PubMed ID: 24007863
[TBL] [Abstract][Full Text] [Related]
10. NDRG1 promotes growth of hepatocellular carcinoma cells by directly interacting with GSK-3β and Nur77 to prevent β-catenin degradation.
Lu WJ; Chua MS; Wei W; So SK
Oncotarget; 2015 Oct; 6(30):29847-59. PubMed ID: 26359353
[TBL] [Abstract][Full Text] [Related]
11. Combination of temsirolimus and adriamycin exhibits an enhanced antitumor effect in hepatocellular carcinoma.
Kang HG; Wang BZ; Zhang J; Liu MR; Li YX
Clin Res Hepatol Gastroenterol; 2017 Mar; 41(2):197-203. PubMed ID: 27863926
[TBL] [Abstract][Full Text] [Related]
12. Human carbonyl reductase 1 upregulated by hypoxia renders resistance to apoptosis in hepatocellular carcinoma cells.
Tak E; Lee S; Lee J; Rashid MA; Kim YW; Park JH; Park WS; Shokat KM; Ha J; Kim SS
J Hepatol; 2011 Feb; 54(2):328-39. PubMed ID: 21056497
[TBL] [Abstract][Full Text] [Related]
13. N-myc downstream regulated gene1/Cap43 overexpression suppresses tumor growth by hepatic cancer cells through cell cycle arrest at the G0/G1 phase.
Akiba J; Murakami Y; Noda M; Watari K; Ogasawara S; Yoshida T; Kawahara A; Sanada S; Yasumoto M; Yamaguchi R; Kage M; Kuwano M; Ono M; Yano H
Cancer Lett; 2011 Nov; 310(1):25-34. PubMed ID: 21775055
[TBL] [Abstract][Full Text] [Related]
14. Selective ablation of Notch3 in HCC enhances doxorubicin's death promoting effect by a p53 dependent mechanism.
Giovannini C; Gramantieri L; Chieco P; Minguzzi M; Lago F; Pianetti S; Ramazzotti E; Marcu KB; Bolondi L
J Hepatol; 2009 May; 50(5):969-79. PubMed ID: 19304334
[TBL] [Abstract][Full Text] [Related]
15. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
[TBL] [Abstract][Full Text] [Related]
16. Synergistically killing activity of aspirin and histone deacetylase inhibitor valproic acid (VPA) on hepatocellular cancer cells.
Li X; Zhu Y; He H; Lou L; Ye W; Chen Y; Wang J
Biochem Biophys Res Commun; 2013 Jun; 436(2):259-64. PubMed ID: 23726914
[TBL] [Abstract][Full Text] [Related]
17. AZD6244 and doxorubicin induce growth suppression and apoptosis in mouse models of hepatocellular carcinoma.
Huynh H; Chow PK; Soo KC
Mol Cancer Ther; 2007 Sep; 6(9):2468-76. PubMed ID: 17876044
[TBL] [Abstract][Full Text] [Related]
18. The cyclin-dependent kinase inhibitor flavopiridol sensitizes human hepatocellular carcinoma cells to TRAIL-induced apoptosis.
Miyashita K; Shiraki K; Fuke H; Inoue T; Yamanaka Y; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T
Int J Mol Med; 2006 Aug; 18(2):249-56. PubMed ID: 16820931
[TBL] [Abstract][Full Text] [Related]
19. [Synergism of antitumor effects on ovarian carcinoma using autocatalytic caspase-3 combined with flavopiridol].
Song Y; Shen K; Xu F
Zhonghua Fu Chan Ke Za Zhi; 2010 Oct; 45(10):781-6. PubMed ID: 21176562
[TBL] [Abstract][Full Text] [Related]
20. WP1130 increases doxorubicin sensitivity in hepatocellular carcinoma cells through usp9x-dependent p53 degradation.
Liu H; Chen W; Liang C; Chen BW; Zhi X; Zhang S; Zheng X; Bai X; Liang T
Cancer Lett; 2015 Jun; 361(2):218-25. PubMed ID: 25749422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]